Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes.

Tricò, Domenico; Raggi, Francesco; Distaso, Mariarosaria; Ferrannini, Ele; Solini, Anna

Tricò, Domenico; Raggi, Francesco; Distaso, Mariarosaria; Ferrannini, Ele; Solini, Anna.

Afiliación

Tricò D; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Raggi F; Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.
Distaso M; Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.
Ferrannini E; Institute of Clinical Physiology, National Research Council, Pisa, Italy.
Solini A; Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy. Electronic address: anna.solini@unipi.it.

Diabetes Res Clin Pract ; 190: 109983, 2022 Aug.

Article en En | MEDLINE | ID: mdl-35803317

Asunto(s)

Diabetes Mellitus Tipo 2; Compuestos de Bencidrilo; Colesterol; LDL-Colesterol; Diabetes Mellitus Tipo 2/complicaciones; Glucosa; Glucósidos; Humanos; Proproteína Convertasa 9; Transportador 2 de Sodio-Glucosa; Subtilisinas

Palabras clave

Empagliflozin; LDL lipoproteins; PCSK9 protein; Proprotein Convertase 9; Sodium-Glucose Transporter 2 Inhibitors; Type 2 Diabetes Mellitus

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 Límite: Humans Idioma: En Revista: Diabetes Res Clin Pract Asunto de la revista: ENDOCRINOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Irlanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google